ArticleClinical therapeutics2011

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.

William J Valentine et al.PubMed ↗Publisher ↗

No numbers read from the abstract.